A clinical-stage biopharmaceutical company advancing the development of new biologics for cancer treatment.  TORL-Bio was founded in 2018 and is focused on the development of novel antibody-based therapeutics for cancer patients.  TORL has currently 3 therapeutics in Ph1 clinical trials in indications such as NSCLC, gastric, pancreatic and ovarian cancers

Clinical Trials

Health Care

Biotechnology

TORL BioTherapeutics, LLC

Mark Alles

Dave Licata

Stephen Letrent

Clinical Operations

Leadership Team

Clinical and Operations Team

Clinical Operations

Other teams at TORL BioTherapeutics, LLC

Leadership Team

Clinical and Operations Team